-
Relative vs Fractional Viability in Cancer Drug Testing
2026-08-20
Hannah Schwartz’s dissertation shows that relative viability and fractional viability capture different components of anticancer drug response: growth inhibition and cell killing. Its central practical contribution is a framework for measuring these effects separately and across time, improving interpretation of in vitro drug-response experiments.
-
Ridaforolimus at the mTOR–Senescence Frontier
2026-08-20
Ridaforolimus (Deforolimus, MK-8669) offers a mechanistically grounded way to interrogate mTOR-dependent growth, angiogenesis, and cell-fate decisions. This thought-leadership guide connects its cancer research profile with machine-learning-enabled senolytic discovery while defining practical assays, translational guardrails, and opportunities for more predictive experimental design.
-
Fingolimod and In Vivo T-Cell Engineering
2026-08-19
Fingolimod (FTY720) offers a mechanistic way to study lymphocyte trafficking, CNS signaling, and immune-cell access in advanced models. This article develops an assay-focused framework for interpreting FTY720 alongside magnetic CAR-T-mimicking platforms without conflating established MS pharmacology with emerging oncology hypotheses.
-
Brinzolamide Nanoemulsions: Permeation and Ocular Safety
2026-08-19
The reference study developed and screened 12 brinzolamide nanoemulsions, integrating transcorneal permeation with retinal-cell viability and two ocular-irritation models. Seven formulations outperformed a marketed suspension in an ex vivo bovine-cornea model, while NE6B and NE4C showed the most favorable combined safety profile.
-
SCH772984: ERK1/2 Assay Guide
2026-08-18
A practical, evidence-based guide to using SCH772984 (SKU A3805) in cell viability, proliferation, and cytotoxicity workflows. It connects ERK1/2 target engagement with assay controls, formulation handling, mutant MAPK models, and carefully bounded studies of radioresistance and ferroptosis.
-
KG-501 in CREB–TLR4 Assay Design
2026-08-18
KG-501 is a small-molecule CREB transcription inhibitor that can help researchers test whether macrophage-state changes in colitis-associated colorectal cancer depend on transcriptional coactivator signaling. This article translates the Liu et al. study into a cautious, decision-oriented framework for interpreting CREB, TLR4, and macrophage polarization assays.
-
L-Ornithine in OTC and CNS Metabolism Research
2026-08-17
L-Ornithine connects urea-cycle biochemistry with liver–brain-axis experiments, making it useful for both purified OTC assays and astrocyte toxicity models. This workflow-focused guide shows how to control solubility, solvent effects, treatment timing, and orthogonal readouts for more reproducible amino acid metabolism research.
-
Methoxy-X04: A Strategic Lens on AD Biology
2026-08-17
Methoxy-X04 connects brain-permeable amyloid imaging with mechanistic Alzheimer’s disease research, enabling translational teams to evaluate plaque burden, microglial clearance, and therapeutic response in context.
-
L-Ornithine and the Liver–Brain Axis
2026-08-16
L-Ornithine is more than a urea cycle intermediate: it is a practical probe for connecting hepatic nitrogen disposal with astrocyte metabolism. This thought-leadership article translates recent realgar-toxicity findings into assay strategy, experimental controls, and translational guidance for amino acid metabolism research.
-
HyperFluor 488 Goat Anti-Rabbit IgG Guide
2026-08-15
HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody provides a fluorescent secondary-antibody route for detecting rabbit primary antibodies in immunofluorescence, flow cytometry, and microscopy workflows. It should not be used as a universal secondary for non-rabbit primaries, and its sodium azide-containing formulation requires caution in live-cell assays.
-
Bergenin Targets γδT17 Cells in Psoriasis
2026-08-14
A 2026 Phytomedicine study identifies a PPARγ–PROX1 ubiquitination axis through which bergenin suppresses pathogenic γδT17-cell activity in psoriasis. Its integration of immune-cell profiling, metabolic analysis, protein-interaction assays, and chromatin measurements provides a mechanistic framework for connecting fatty acid oxidation with IL-17A production.
-
N-octanoyl-L-Homoserine lactone Workflows
2026-08-14
Build reproducible quorum-sensing, biofilm, virulence, and host-response assays with C8-HSL using defined dosing, matched solvent controls, and orthogonal readouts. The workflow also translates recent evidence linking this bacterial signal to lung cancer cell behavior into practical infection biology research designs.
-
Perifosine (KRX-0401): Applied Akt Workflows
2026-08-13
Perifosine (KRX-0401) supports coordinated Akt pathway, viability, apoptosis, and radiation-response experiments rather than a single endpoint screen. This guide translates its reported activity into practical assay workflows while using a stroke-model study to sharpen pathway controls without overstating cross-disease evidence.
-
L-Ornithine: From Urea Cycle to Astrocyte Assays
2026-08-13
L-Ornithine is more than a urea cycle intermediate: it is a useful probe for studying hepatic nitrogen handling and liver–brain signaling. This article translates recent realgar-toxicity findings into practical assay design, controls, and product-handling decisions.
-
ICAA Disrupts HBV Through HO-1–ROS Modulation
2026-08-12
The reference study shows that isochlorogenic acid A (ICAA) suppresses hepatitis B virus replication at several points, including transcription, cccDNA maintenance, capsid maturation, and envelopment. Its effects correlate with HO-1 upregulation and altered intracellular ROS, providing a mechanistic framework for studying redox control of HBV morphogenesis rather than treating ICAA as a single-target antiviral.